|
5/15/2013 4:38:38 PM
|
Nordion Signs Contract Manufacturing Agreement With Navidea Biopharmaceuticals
|
|
5/15/2013 4:34:16 PM
|
Navidea Biopharma Signs Manufacturing And Supply Agreement With Nordion
|
|
5/8/2013 7:05:52 AM
|
Navidea Biopharmaceuticals Q1 Loss Per Share $0.06 Vs. Loss $0.07 Last Year
|
|
5/1/2013 7:07:40 AM
|
Navidea Announces U.S. Launch Of Lymphoseek Injection
|
|
4/24/2013 8:46:08 AM
|
Navidea Biopharmaceuticals Announces Underwritten Sale Of Common Stock
|
|
4/5/2013 9:01:19 AM
|
Navidea Biopharma Retains Stern IR For Investor Relations Services
|
|
4/5/2013 8:30:40 AM
|
|
|
4/4/2013 12:31:28 PM
|
|
|
4/4/2013 8:18:28 AM
|
|
|
4/4/2013 8:08:04 AM
|
Navidea Biopharma Says Lymphoseek Met Primary Efficacy Endpoint Of Accurately Identifying Sentinel Lymph Nodes
|
|
4/3/2013 9:35:38 PM
|
|
|
3/27/2013 10:32:21 PM
|
|
|
3/27/2013 10:30:06 AM
|
|
|
3/27/2013 9:17:31 AM
|
Navidea Biopharma Announces Enrollment Of First Subject In Phase 2b Trial Of NAV4694 In Subjects With MCI
|
|
3/21/2013 9:15:58 AM
|
|
|
3/21/2013 9:06:32 AM
|
Navidea Biopharma: Lymphoseek Phase 3 Clinical Trial Meets Primary Efficacy Endpoint In Breast Cancer
|
|
3/13/2013 1:40:49 PM
|
|
|
3/13/2013 1:12:56 PM
|
Navidea Biopharma Announces FDA Approval Of Lymphoseek Injection For Use In Lymphatic Mapping
|
|
3/7/2013 7:30:16 AM
|
|
|
3/6/2013 4:53:25 PM
|
Navidea Biopharma Posts Q4 Loss Per Share Of $0.07 Vs. Loss $0.08 Year Ago
|